GE announces availability of Pixxoscan in Canada

MISSISSAUGA, Ont. – GE HealthCare Canada Inc. announced the availability of Pixxoscan (gadobutrol), its macrocyclic, non-ionic Magnetic Resonance Imaging (MRI) gadolinium-based contrast agent (GBCA) during the Canadian Association of Radiology Annual Scientific Meeting in Montreal.

Already approved in countries in Europe, Pixxoscan is a bioequivalent, fully substitutable generic for Gadovist, having the same qualitative and quantitative composition in active substance and pharmaceutical form as the reference listed drug. Pixxoscan expands GE HealthCare’s contrast media portfolio which also includes Omniscan (gadodiamide), Omnipaque (iohexol) and Visipaque (iodixanol).

Pixxoscan facilitates visualization of abnormal structures or lesions and helps in the differentiation between healthy and pathological tissue during MRI procedures. It has a high relaxivity, which helps enhance detection, delineation and characterization in MRI across its range of indications.

Pixxoscan (gadobutrol injection) is approved by Health Canada and indicated in adults and children of all ages including term newborns for:

• Contrast enhancement during cranial and spinal MRI investigations and for contrast-enhanced magnetic resonance angiography (CE-MRA).
• Contrast enhanced MRI of the breast to assess the presence and extent of malignant breast disease, and MRI of the kidney.

Pixxoscan is particularly suited for cases where the exclusion or demonstration of additional pathology may influence the choice of therapy or patient management, for detection of very small lesions and for visualization of tumours that do not readily take up contrast media. Pixxoscan is also suited for perfusion studies for the diagnosis of stroke, detection of focal cerebral ischemia and tumor perfusion.

“Expanding our portfolio with Pixxoscan will allow us to provide hospitals and radiology departments in Canada more choices when it comes to meeting their diagnostic needs,” said Mike Hamilton (pictured), president of GE HealthCare in Canada. “We know healthcare professionals will continue to require innovative diagnostic solutions to provide optimal care for patients and we are committed to enabling them with the right tools to do so both now and into the future.”

Pixxoscan is offered in multiple formats, including glass vials and larger volume polymer bottle packaging. As with all GE HealthCare contrast agents, Pixxoscan is being produced in compliance with current Good Manufacturing Practices (cGMP).

GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents which supported over 130 million patient procedures in 2024, equivalent to four patient procedures every second. For more than 40 years, GE HealthCare imaging agents have been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.

About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.